Abstract
This study tested the hypothesis that obesity alters the cardiac response to ischemia/reperfusion and/or glucagon like peptide-1 (GLP-1) receptor activation, and that these differences are associated with alterations in the obese cardiac proteome and microRNA (miRNA) transcriptome. Ossabaw swine were fed normal chow or obesogenic diet for 6 months. Cardiac function was assessed at baseline, during a 30-minutes coronary occlusion, and during 2 hours of reperfusion in anesthetized swine treated with saline or exendin-4 for 24 hours. Cardiac biopsies were obtained from normal and ischemia/reperfusion territories. Fat-fed animals were heavier, and exhibited hyperinsulinemia, hyperglycemia, and hypertriglyceridemia. Plasma troponin-I concentration (index of myocardial injury) was increased following ischemia/reperfusion and decreased by exendin-4 treatment in both groups. Ischemia/reperfusion produced reductions in systolic pressure and stroke volume in lean swine. These indices were higher in obese hearts at baseline and relatively maintained throughout ischemia/reperfusion. Exendin-4 administration increased systolic pressure in lean swine but did not affect the blood pressure in obese swine. End-diastolic volume was reduced by exendin-4 following ischemia/reperfusion in obese swine. These divergent physiologic responses were associated with obesity-related differences in proteins related to myocardial structure/function (e.g. titin) and calcium handling (e.g. SERCA2a, histidine-rich Ca2+ binding protein). Alterations in expression of cardiac miRs in obese hearts included miR-15, miR-27, miR-130, miR-181, and let-7. Taken together, these observations validate this discovery approach and reveal novel associations that suggest previously undiscovered mechanisms contributing to the effects of obesity on the heart and contributing to the actions of GLP-1 following ischemia/reperfusion.
Similar content being viewed by others
References
Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF (2006) Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355:763–778. doi:10.1056/NEJMoa055643
Ahmed SH, Lindsey ML (2009) Titin phosphorylation: myocardial passive stiffness regulated by the intracellular giant. Circ Res 105:611–613. doi:10.1161/CIRCRESAHA.109.206912
Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA (2014) Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management. Transl Res 164:345–356. doi:10.1016/j.trsl.2014.04.010
Aurora AB, Mahmoud AI, Luo X, Johnson BA, van Rooij E, Matsuzaki S, Humphries KM, Hill JA, Bassel-Duby R, Sadek HA, Olson EN (2012) MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca(2)(+) overload and cell death. J Clin Investig 122:1222–1232. doi:10.1172/JCI59327
Balderas-Villalobos J, Molina-Munoz T, Mailloux-Salinas P, Bravo G, Carvajal K, Gomez-Viquez NL (2013) Oxidative stress in cardiomyocytes contributes to decreased SERCA2a activity in rats with metabolic syndrome. Am J Physiol Heart Circ Physiol 305:H1344–H1353. doi:10.1152/ajpheart.00211.2013
Ballo P, Motto A, Mondillo S, Faraguti SA (2007) Impact of obesity on left ventricular mass and function in subjects with chronic volume overload. Obesity (Silver Spring) 15:2019–2026. doi:10.1038/oby.2007.241
Bastien M, Poirier P, Lemieux I, Despres JP (2014) Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 56:369–381. doi:10.1016/j.pcad.2013.10.016
Berwick ZC, Dick GM, Tune JD (2012) Heart of the matter: coronary dysfunction in metabolic syndrome. J Mol Cell Cardiol 52:848–856. doi:10.1016/j.yjmcc.2011.06.025
Borbouse L, Dick GM, Asano S, Bender SB, Dincer UD, Payne GA, Neeb ZP, Bratz IN, Sturek M, Tune JD (2009) Impaired function of coronary BK(Ca) channels in metabolic syndrome. Am J Physiol Heart Circ Physiol 297:H1629–H1637. doi:10.1152/ajpheart.00466.2009
Bourajjaj M, Armand AS, da Costa Martins PA, Weijts B, van der Nagel R, Heeneman S, Wehrens XH, De Windt LJ (2008) NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem 283:22295–22303. doi:10.1074/jbc.M801296200
Bugger H, Abel ED (2014) Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57:660671. doi:10.1007/s00125-014-3171-6
Burkhoff D, Mirsky I, Suga H (2005) Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 289:H501–H512. doi:10.1152/ajpheart.00138.2005
Chugh S, Suen C, Gramolini A (2010) Proteomics and mass spectrometry: what have we learned about the heart? Curr Cardiol Rev 6:124–133. doi:10.2174/157340310791162631
Cieniewski-Bernard C, Mulder P, Henry JP, Drobecq H, Dubois E, Pottiez G, Thuillez C, Amouyel P, Richard V, Pinet F (2008) Proteomic analysis of left ventricular remodeling in an experimental model of heart failure. J Proteome Res 7:5004–5016. doi:10.1021/pr800409u
Colombo MG, Meisinger C, Amann U, Heier M, von Scheidt W, Kuch B, Peters A, Kirchberger I (2015) Association of obesity and long-term mortality in patients with acute myocardial infarction with and without diabetes mellitus: results from the MONICA/KORA myocardial infarction registry. Cardiovasc Diabetol 14:24. doi:10.1186/s12933-015-0189-0
Crowley DI, Khoury PR, Urbina EM, Ippisch HM, Kimball TR (2011) Cardiovascular impact of the pediatric obesity epidemic: higher left ventricular mass is related to higher body mass index. J Pediatr 158(709–714):e701. doi:10.1016/j.jpeds.2010.10.016
de Weger RA, Schipper ME, Siera-de Koning E, van der Weide P, van Oosterhout MF, Quadir R, Steenbergen-Nakken H, Lahpor JR, de Jonge N, Bovenschen N (2011) Proteomic profiling of the human failing heart after left ventricular assist device support. J Heart Lung Transplant 30:497–506. doi:10.1016/j.healun.2010.11.011
Dineen SL, McKenney ML, Bell LN, Fullenkamp AM, Schultz KA, Alloosh M, Chalasani N, Sturek M (2015) Metabolic syndrome abolishes glucagon-like peptide 1 receptor agonist stimulation of SERCA in coronary smooth muscle. Diabetes 64:3321–3327. doi:10.2337/db14-1790
Fredersdorf S, Thumann C, Zimmermann WH, Vetter R, Graf T, Luchner A, Riegger GA, Schunkert H, Eschenhagen T, Weil J (2012) Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: in vivo and in vitro data. Cardiovasc Diabetol 11:57. doi:10.1186/1475-2840-11-57
Gejl M, Sondergaard HM, Stecher C, Bibby BM, Moller N, Botker HE, Hansen SB, Gjedde A, Rungby J, Brock B (2012) Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J Clin Endocrinol Metab 97:E1165–E1169. doi:10.1210/jc.2011-3456
Goodwill AG, Mather KJ, Conteh AM, Sassoon DJ, Noblet JN, Tune JD (2014) Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev Endocr Metab Disord 15:209–217. doi:10.1007/s11154-014-9290-z
Goodwill AG, Tune JD, Noblet JN, Conteh AM, Sassoon D, Casalini ED, Mather KJ (2014) Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. Basic Res Cardiol 109:426. doi:10.1007/s00395-014-0426-9
Greco S, Fasanaro P, Castelvecchio S, D’Alessandra Y, Arcelli D, Di Donato M, Malavazos A, Capogrossi MC, Menicanti L, Martelli F (2012) MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 61:1633–1641. doi:10.2337/db11-0952
Grueter CE, van Rooij E, Johnson BA, DeLeon SM, Sutherland LB, Qi X, Gautron L, Elmquist JK, Bassel-Duby R, Olson EN (2012) A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149:671–683. doi:10.1016/j.cell.2012.03.029
Hamdani N, Franssen C, Lourenco A, Falcao-Pires I, Fontoura D, Leite S, Plettig L, Lopez B, Ottenheijm CA, Becher PM, Gonzalez A, Tschope C, Diez J, Linke WA, Leite-Moreira AF, Paulus WJ (2013) Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail 6:1239–1249. doi:10.1161/CIRCHEARTFAILURE.113.000539
Hamdani N, Hervent AS, Vandekerckhove L, Matheeussen V, Demolder M, Baerts L, De Meester I, Linke WA, Paulus WJ, De Keulenaer GW (2014) Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. Cardiovasc Res 104:423–431. doi:10.1093/cvr/cvu223
Hogan PG, Chen L, Nardone J, Rao A (2003) Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17:2205–2232. doi:10.1101/gad.1102703
Huggett RJ, Burns J, Mackintosh AF, Mary DA (2004) Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 44:847–852. doi:10.1161/01.HYP.0000147893.08533.d8
Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, Latimer PA, Hare JM, Olson EN, van Rooij E (2012) Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 110:71–81. doi:10.1161/CIRCRESAHA.111.244442
Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15. doi:10.1093/nar/gng015
Knudson JD, Dincer UD, Bratz IN, Sturek M, Dick GM, Tune JD (2007) Mechanisms of coronary dysfunction in obesity and insulin resistance. Microcirculation 14:317–338. doi:10.1080/10739680701282887
Kragelund C, Hassager C, Hildebrandt P, Torp-Pedersen C, Kober L, Group TS (2005) Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol 98:123–131. doi:10.1016/j.ijcard.2004.03.042
Kruger M, Linke WA (2011) The giant protein titin: a regulatory node that integrates myocyte signaling pathways. J Biol Chem 286:9905–9912. doi:10.1074/jbc.R110.173260
Lauer MS, Anderson KM, Kannel WB, Levy D (1991) The impact of obesity on left ventricular mass and geometry. The Framingham heart study. JAMA 266:231–236. doi:10.1001/jama.1991.03470020057032
Lee IS, Park KC, Yang KJ, Choi H, Jang YS, Lee JM, Kim HS (2015) Exenatide reverses dysregulated microRNAs in high-fat diet-induced obese mice. Obes Res Clin Pract. doi:10.1016/j.orcp.2015.07.011
Leopold JA (2015) Obesity-related cardiomyopathy is an adipocyte-mediated paracrine disease. Trends Cardiovasc Med 25:127–128. doi:10.1016/j.tcm.2014.09.010
LeWinter MM, Granzier H (2010) Cardiac titin: a multifunctional giant. Circulation 121:2137–2145. doi:10.1161/CIRCULATIONAHA.109.860171
Limpitikul WB, Dick IE, Joshi-Mukherjee R, Overgaard MT, George AL Jr, Yue DT (2014) Calmodulin mutations associated with long QT syndrome prevent inactivation of cardiac L-type Ca(2+) currents and promote proarrhythmic behavior in ventricular myocytes. J Mol Cell Cardiol 74:115–124. doi:10.1016/j.yjmcc.2014.04.022
Liu LF, Liang Z, Lv ZR, Liu XH, Bai J, Chen J, Chen C, Wang Y (2012) MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury. J Geriatr Cardiol 9:28–32. doi:10.3724/SP.J.1263.2012.00028
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207–258. doi:10.1152/physrev.00015.2009
Mahajan R, Lau DH, Sanders P (2015) Impact of obesity on cardiac metabolism, fibrosis, and function. Trends Cardiovasc Med 25:119–126. doi:10.1016/j.tcm.2014.09.005
Martin-Vaquero P, da Costa RC, Allen MJ, Moore SA, Keirsey JK, Green KB (2015) Proteomic analysis of cerebrospinal fluid in canine cervical spondylomyelopathy. Spine (Phila Pa 1976) 40:601–612. doi:10.1097/BRS.0000000000000831
Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G et al (1995) Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92:778–784. doi:10.1161/01.CIR.92.4.778
Moberly SP, Mather KJ, Berwick ZC, Owen MK, Goodwill AG, Casalini ED, Hutchins GD, Green MA, Ng Y, Considine RV, Perry KM, Chisholm RL, Tune JD (2013) Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol 108:365. doi:10.1007/s00395-013-0365-x
Molkentin JD (2004) Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 63:467–475. doi:10.1016/j.cardiores.2004.01.021
Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, Streutker C, Holland D, Cao X, Baggio LL, Drucker DJ (2013) GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(−/−) mice. Endocrinology 154:127–139. doi:10.1210/en.2012-1937
Paulino EC, Ferreira JC, Bechara LR, Tsutsui JM, Mathias W Jr, Lima FB, Casarini DE, Cicogna AC, Brum PC, Negrao CE (2010) Exercise training and caloric restriction prevent reduction in cardiac Ca2+-handling protein profile in obese rats. Hypertension 56:629–635. doi:10.1161/HYPERTENSIONAHA.110.156141
Pinto TE, Gusso S, Hofman PL, Derraik JG, Hornung TS, Cutfield WS, Baldi JC (2014) Systolic and diastolic abnormalities reduce the cardiac response to exercise in adolescents with type 2 diabetes. Diabetes Care 37:1439–1446. doi:10.2337/dc13-2031
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH, American Heart A, Obesity Committee of the Council on Nutrition PA, Metabolism (2006) Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113:898–918. doi:10.1161/CIRCULATIONAHA.106.171016
Porrello ER, Mahmoud AI, Simpson E, Johnson BA, Grinsfelder D, Canseco D, Mammen PP, Rothermel BA, Olson EN, Sadek HA (2013) Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc Natl Acad Sci USA 110:187–192. doi:10.1073/pnas.1208863110
Rana JS, Mukamal KJ, Morgan JP, Muller JE, Mittleman MA (2004) Obesity and the risk of death after acute myocardial infarction. Am Heart J 147:841–846. doi:10.1016/j.ahj.2003.12.015
Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, Vatner DE, Vatner SF, Abdellatif M (2009) Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 104:879–886. doi:10.1161/CIRCRESAHA.108.193102
Rezaul K, Wu L, Mayya V, Hwang SI, Han D (2005) A systematic characterization of mitochondrial proteome from human T leukemia cells. Mol Cell Proteomics 4:169–181. doi:10.1074/mcp.M400115-MCP200
Rodriguez RH, Bickta JL, Murawski P, O’Donnell CP (2014) The impact of obesity and hypoxia on left ventricular function and glycolytic metabolism. Physiol Rep 2:e12001. doi:10.14814/phy2.12001
Schulz R, Rose J, Martin C, Brodde OE, Heusch G (1993) Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 88:684–695. doi:10.1161/01.CIR.88.2.684
Shen Y, Shen Z, Miao L, Xin X, Lin S, Zhu Y, Guo W, Zhu YZ (2015) miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-gamma-lyase expression. Antioxid Redox Signal 22:224–240. doi:10.1089/ars.2014.5909
Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440–9445. doi:10.1073/pnas.1530509100
Suga H (1990) Ventricular energetics. Physiol Rev 70:247–277
ter Keurs HE (2012) The interaction of Ca2+ with sarcomeric proteins: role in function and dysfunction of the heart. Am J Physiol Heart Circ Physiol 302:H38–H50. doi:10.1152/ajpheart.00219.2011
Trask AJ, Katz PS, Kelly AP, Galantowicz ML, Cismowski MJ, West TA, Neeb ZP, Berwick ZC, Goodwill AG, Alloosh M, Tune JD, Sturek M, Lucchesi PA (2012) Dynamic micro- and macrovascular remodeling in coronary circulation of obese Ossabaw pigs with metabolic syndrome. J Appl Physiol 113:1128–1140. doi:10.1152/japplphysiol.00604.2012
Wang C, Li Q, Wang W, Guo L, Guo C, Sun Y, Zhang J (2015) GLP-1 contributes to increases in PGC-1alpha expression by downregulating miR-23a to reduce apoptosis. Biochem Biophys Res Commun 466:33–39. doi:10.1016/j.bbrc.2015.08.092
Wang Z (2013) miRNA in the regulation of ion channel/transporter expression. Compr Physiol 3:599–653. doi:10.1002/cphy.c110002
Wende AR (2015) Post-translational modifications of the cardiac proteome in diabetes and heart failure. Proteom Clin Appl. doi:10.1002/prca.201500052
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, Investigators E (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335. doi:10.1056/NEJMoa1305889
Wong CY, O’Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH (2004) Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 110:3081–3087. doi:10.1161/01.CIR.0000147184.13872.0F
Yakinci C, Mungen B, Karabiber H, Tayfun M, Evereklioglu C (2000) Autonomic nervous system functions in obese children. Brain Dev 22:151–153. doi:10.1016/S0387-7604(00)00094-2
Younce CW, Burmeister MA, Ayala JE (2013) Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol 304:C508–C518. doi:10.1152/ajpcell.00248.2012
Zhao SM, Wang YL, Guo CY, Chen JL, Wu YQ (2014) Progressive decay of Ca2 + homeostasis in the development of diabetic cardiomyopathy. Cardiovasc Diabetol 13:75. doi:10.1186/1475-2840-13-75
Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M, Redfield MM, Bull DA, Granzier HL, LeWinter MM (2015) Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131:1247–1259. doi:10.1161/CIRCULATIONAHA.114.013215
Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, Investigators L-S (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 32:1224–1230. doi:10.2337/dc08-2124
Acknowledgments
This work was supported by the National Institutes of Health grant, HL117620 (J. Tune and K. Mather, PI). Dr. Goodwill was supported by American Heart Association 13POST1681001813 (A. Goodwill, PI). Mr. Conteh was supported by National Institutes of Health HL117620-S1 (J. Tune and K. Mather, PI). Mr. Sassoon and Ms. Noblet were supported by grant number TL1 TR000162 (A. Shekhar, PI) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. The authors also thank Arpad Somogyi and the Proteomics Core at The Ohio State University for performing protein extraction and mass spectrometry. The authors would also like to thank Jeanette McClintick and the Indiana University Center for Medical Genomics for performing miR microarrays. Ingenuity Pathway Analyses were made possible by a collaboration with WV-INBRE (supported by NIH Grant P20GM103434).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Sassoon, D.J., Goodwill, A.G., Noblet, J.N. et al. Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism. Basic Res Cardiol 111, 43 (2016). https://doi.org/10.1007/s00395-016-0563-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00395-016-0563-4